A Promising New Era in Cancer Treatment
One of the most exciting advances in cancer is an innovative approach that involves removing a patient’s immune cells, engineering those cells to identify cancer, then infusing those cells in the patient to kill cancer. We have long believed in the promise of engineering T cells to treat certain blood cancers and our singular focus is developing cell therapy.
We are developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Our dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.
We have one of the leading pipelines in cell therapy within the industry. Our CAR pipeline currently includes our lead investigational therapy that has the potential to become a franchise and address a range of blood cancers, and next generation technologies. Our TCR pipeline includes investigational therapies that have the potential to address a range of solid tumors.
Our most advanced investigational therapy, axicabtagene ciloleucel, has been submitted to the U.S. Food and Drug Administration for the treatment of patients with aggressive non-Hodgkin lymphoma (NHL). Additional indications are being pursued for axicabtagene ciloleucel and the KTE-C19 development program as well as for our TCR pipeline and second generation technology. We expect these indications to cover a variety of blood cancers and solid tumors.
Expanded access programs allows for potential access to investigational therapies in certain rare circumstances for patients who unable to participate in an ongoing clinical trial or whose treatment options are otherwise limited. For more information regarding Kite’s expanded access policy, please click on the link below.